Successful Cord Blood Transplantation in a Werner Syndrome Patient with High-risk Myelodysplastic Syndrome

Internal Medicine
Kiyohito HayashiHideho Wada

Abstract

Werner syndrome (WS) confers a high risk of the development of neoplasias, including hematological malignancies, and curative treatment for these malignancies is difficult to achieve. A 44-year-old man with myelodysplastic syndrome was admitted to our hospital. He was diagnosed with mutation-proven WS. He underwent cord blood transplantation (CBT) following fludarabine, busulfan, and melphalan administration. A chimerism analysis of his marrow blood on day 62 showed a donor pattern >95%, which confirmed engraftment. The patient lived for 15 months while maintaining remission of MDS without treatment-related toxicity. Our case shows that CBT can be a treatment modality for WS patients with hematological malignancies.

References

Jan 1, 1994·Acta Haematologica·L UndarG Karpuzoğlu
May 5, 2006·Human Mutation·Shurong HuangJunko Oshima
Nov 1, 2006·Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·Masayuki OchiTetsurou Miki
Apr 14, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Stefan O Ciurea, Borje S Andersson
Oct 12, 2010·Seminars in Cancer Biology·Raymond J Monnat
Jul 24, 2012·Geriatrics & Gerontology International·Minoru TakemotoKoutaro Yokote
Jul 22, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sameem AbedinDaniel R Couriel
Dec 17, 2014·Virchows Archiv : an International Journal of Pathology·Yoshito SadahiraMakoto Goto
Jun 28, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Hisashi YamamotoShuichi Taniguchi

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
MDS

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.